Sio Gene Therapies Ends Gene Therapy Program for Parkinson's Disease, Names New CEO-- Sio Gene Therapies on Monday said that it intends to end its licensing deal with Oxford Biomedica for AXO-Lenti-PD, its lentiviral gene therapy program for Parkinson's disease, and will instead...